For the Inventor, By the Inventor

Enter assignee name

St. Louis, MO, United States of America

Pharmacia Corporation

Calculating rank

USPTO Granted Patents = 220

% Expired Patents = 60.5

CIPO Patents = 11

EPO Patents = 6

Trademarks = 17

Forward Citations = 2,919

Loading Chart...

Loading Chart...

535 inventors (with patents filed for the assignee):

Melvin L Rueppel (30 out of 53 patents)

James A Sikorski (30 out of 130 patents)

Richard C Durley (26 out of 49 patents)

4. Deborah A Mischke (24 out of 57 patents)

5. Michael B Tollefson (24 out of 45 patents)

6. John Jeffrey Talley (23 out of 228 patents)

7. Lijuan Jane Wang (22 out of 44 patents)

8. Brian S Hickory (22 out of 41 patents)

9. Michael S South (22 out of 32 patents)

10. Yvette M Fobian (22 out of 47 patents)

11. William F Vernier (21 out of 39 patents)

12. Margaret Lanahan Grapperhaus (19 out of 42 patents)

13. Monica B Norton (19 out of 39 patents)

14. Ashton T Hamme (19 out of 37 patents)

15. Dale P Spangler (19 out of 47 patents)

Core Competencies:

Pramipexole

Growth Hormone

Pyrimidinones

Biomaterials

Protease Inhibitors

Integrin Antagonists

Nitric Oxide Synthase

Cyclooxygenase Inhibitors

Pyrazoles

Gastrointestinal Disorders

Cancer Treatment

Ophthalmic Formulations

220 patents: Sort by Forward Citations

1. 8679533 - Pramipexole once-daily dosage form (2014-03-25),

2. 8338374 - Stable growth hormone liquid formulation (2012-12-25),

3. 7795271 - Substituted pyrimidinones (2010-09-14),

4. 7445641 - Biomaterials modified with superoxide dismutase mimics (2008-11-04),

5. 7420061 - Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors (2008-09-02),

6. 7320996 - Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer (2008-01-22),

7. 7312333 - Retroviral protease inhibitors (2007-12-25),

8. 7259266 - Benzopyran compounds useful for treating inflammatory conditions (2007-08-21),

9. 7238507 - [object Object] (2007-07-03),

10. 7211686 - Process for making optically active α-amino ketones and selected novel optically active α-amino ketones (2007-05-01),

11. 7196118 - Amidino compounds useful as nitric oxide synthase inhibitors (2007-03-27),

12. 7186743 - Substituted pyrazolyl compounds for the treatment of inflammation (2007-03-06),

13. 7183287 - Substituted pyrimidinones (2007-02-27),

14. 7172769 - Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect (2007-02-06),

15. 7153959 - Substituted pyrazoles as p38 kinase inhibitors (2006-12-26),

Company Overview

Pharmacia Corporation, headquartered in St. Louis, MO, specializes in the development and manufacturing of pharmaceutical formulations. The company is recognized for its innovative work in various therapeutic areas, including pramipexole for movement disorders and growth hormone therapies. Its research encompasses a range of core technology topics such as pyrimidinones, biomaterials, protease inhibitors, integrin antagonists, nitric oxide synthase, and cyclooxygenase inhibitors, contributing significantly to advancements in healthcare.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

220 Patents

#19 in St. Louis, MO

#28 in Missouri

#1,910 in US

#3,896 in the World

St. Louis, MO, United States of America

Pharmacia Corporation

Forward Citations = 2,919

535 inventors:

Melvin L Rueppel (30 out of 53 patents)

James A Sikorski (30 out of 130 patents)

Richard C Durley (26 out of 49 patents)

4. Deborah A Mischke (24 out of 57 patents)

5. Michael B Tollefson (24 out of 45 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pharmacia Corporation. Retrieved from https://idiyas.com/company/pharmacia

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…